RVL Pharmaceuticals announced today that its prescription eye drop, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as a 2024 Shape Skin Award winner by Shape Magazine, named “Best for Lift” in the professional category. This is the third Shape award for Upneeq. The product was also named as a “Best Professional Grade” treatment by editors in 2022 and received a 2023 Shape Beauty Award for “Best In-Office” treatments. Upneeq is FDA approved for the treatment of acquired ptosis (droopy eyelids) in adults.
For the 2024 Shape Skin Awards, editors tested over 225 expert-backed face, body, and hair products, facial devices, and aesthetic medical treatments, consulting with board-certified industry experts and researching over a dozen published skincare studies to inform the winning selections. Products were evaluated for their effectiveness, innovation, and performance. 37 winners were ultimately chosen, and judges awarded Upneeq for its subtle but noticeable lift for droopy eyelids.
“We are incredibly grateful to Shape Magazine for recognizing Upneeq as a top player in the beauty industry for the third year in a row and are honored to be named as the ‘Best for Lift’,” said Jennifer Hanlon, Head of Digital Marketing and Consumer Technology at RVL Pharmaceuticals. “Shape is an empowering and trusted voice in health and beauty with a committed community to quality self-care. Being a part of this awards program, supported by editors and industry experts alike, is a testament to Upneeq’s performance and impact.”
Upneeq is a one-of-a-kind, daily eyedrop for adult patients with acquired ptosis that lifts the eyelid to create a more open eye area. Upneeq is available at eye care, dermatology, plastic surgery and medical aesthetic practices nationwide, as well as SkinSolutions.MD via telehealth appointment. In clinical trials, Upneeq demonstrated statistically significant improvements compared to placebo in both superior visual field and eyelid lift, as measured in two pivotal double-masked efficacy studies. The most common adverse reactions with Upneeq (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache.
